Teva acquires worldwide rights to BXCL501 from BioXcel Therapeutics
TEVA•Teva completed its acquisition of BioXcel Therapeutics assets, including worldwide rights to investigational agitation treatment BXCL501. FDA review covers at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults.
1. Acquisition completed
Teva completed its acquisition of BioXcel Therapeutics assets, including worldwide rights to investigational treatment BXCL501. FDA review covers the drug as an at-home treatment for acute agitation associated with schizophrenia or bipolar I or II disorder in adults.
2. Potential treatment
If approved, BXCL501 would be the first FDA-approved at-home treatment for this condition and would expand Teva’s late-stage neuroscience pipeline.
